Clinical Trials Browser

INDUSTRY × 30 days × Clear all

NCT01804686 2026-06-05

CAN3001

Phase 3 Recruiting

LymphoidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT01946204 2026-06-05

SPARTAN

Phase 3 Active not recruiting

1,207 enrolled 15 charts 1 FDA

Prostatic Neoplasms

NCT02123758 2026-06-05

A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer

Phase 1 Active not recruiting

Prostatic Neoplasms

NCT02257736 2026-06-05

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

Phase 3 Active not recruiting

982 enrolled 15 charts

Prostatic Neoplasms

NCT02365597 2026-06-05

An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

Phase 2 Active not recruiting

239 enrolled 32 charts 1 FDA

Urothelial Cancer

NCT02489318 2026-06-05

TITAN

Phase 3 Active not recruiting

1,052 enrolled 13 charts 1 FDA

Prostatic Neoplasms

NCT02531516 2026-06-05

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT02592317 2026-06-05

A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer

Phase 1 Active not recruiting

Prostatic Neoplasms, Castration-Resistant

NCT02609776 2026-06-05

CHRYSALIS

Phase 1 Active not recruiting

751 enrolled 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT02808780 2026-06-05

OPAL

Active not recruiting

Colitis, Ulcerative, Lymphoma, Neoplasms

NCT03145181 2026-06-05

MajesTEC-1

Phase 1 Active not recruiting

302 enrolled 1 FDA

Other hematologic neoplasm

Hematologic Neoplasms

NCT03178552 2026-06-05

B-FAST

Phase 2/3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03399799 2026-06-05

MonumenTAL-1

Phase 1 Active not recruiting

279 enrolled 1 FDA

Other hematologic neoplasm

Hematologic Neoplasms

NCT03417115 2026-06-05

OPAL

Breast Neoplasms

NCT03460977 2026-06-05

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Phase 1 Recruiting

LymphoidThoracic

Lymphoma, Follicular, Recurrence, Small Cell Lung Carcinoma

NCT03486873 2026-06-05

MK-3475-587

Phase 3 Recruiting

Other hematologic neoplasm

Hematologic Neoplasms

NCT03523442 2026-06-05

A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer

Phase 1 Active not recruiting

Prostatic Neoplasms

NCT03748641 2026-06-05

MAGNITUDE

Phase 3 Active not recruiting

765 enrolled 16 charts 1 FDA

Prostatic Neoplasms, Castration-Resistant

NCT03767244 2026-06-05

PROTEUS

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT04108195 2026-06-05

A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

Phase 1 Active not recruiting

Multiple Myeloma

NCT04108208 2026-06-05

A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)

Phase 4 Active not recruiting

75 enrolled 9 charts

Prostatic Neoplasms

NCT04133636 2026-06-05

CARTITUDE-2

Phase 2 Active not recruiting

Multiple Myeloma

NCT04258033 2026-06-05

KUNPENG

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT04325828 2026-06-05

YATAGARASU

Phase 2 Active not recruiting

31 enrolled 15 charts

Salivary Gland Neoplasms

NCT04351555 2026-06-05

NeoADAURA

Phase 3 Active not recruiting

358 enrolled 23 charts

Carcinoma, Non-Small-Cell Lung

NCT04497844 2026-06-05

AMPLITUDE

Phase 3 Active not recruiting

696 enrolled 15 charts 1 FDA

Metastatic Castration-sensitive Prostate Cancer

NCT04557059 2026-06-05

PRIMORDIUM

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT04577833 2026-06-05

A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer

Phase 1 Active not recruiting

Prostatic Neoplasms

NCT04606381 2026-06-05

PALOMA

Phase 1 Active not recruiting

Neoplasms

NCT04621669 2026-06-05

Drug-durg Interaction of SHR3680 With Digoxin, Rosuvastatin Calcium and Metformin Hydrochloride

Phase 1 Completed

Drug-drug Interaction,SHR3680

NCT04634552 2026-06-05

MonumenTAL-1

Phase 2 Recruiting

510 enrolled 1 FDA

Other hematologic neoplasmPlasma cell

Multiple Myeloma, Hematologic Neoplasms

NCT04634877 2026-06-05

KEYNOTE-B21

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT04640623 2026-06-05

SunRISe-1

Phase 2 Active not recruiting

220 enrolled 1 FDA

Urinary Bladder Neoplasms

NCT04644770 2026-06-05

A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer

Phase 1 Active not recruiting

Adenocarcinoma, Prostatic Neoplasms

NCT04658862 2026-06-05

SunRISe-2

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT04662580 2026-06-05

ARX517

Phase 1 Active not recruiting

Prostatic Neoplasms

NCT04696809 2026-06-05

A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Completed

Other hematologic neoplasm

Hematologic Neoplasms

NCT04722146 2026-06-05

MajesTEC-2

Phase 1 Active not recruiting

Multiple Myeloma

NCT04892173 2026-06-05

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

Phase 3 Recruiting

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT04898634 2026-06-05

A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer

Phase 1 Active not recruiting

Prostatic Neoplasms

NCT04923893 2026-06-05

CARTITUDE-5

Phase 3 Active not recruiting

Multiple Myeloma

NCT04936308 2026-06-05

SOLSTICE

Phase 3 Active not recruiting

453 enrolled 25 charts

Arthritis, Psoriatic

NCT04971226 2026-06-05

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Phase 3 Active not recruiting

405 enrolled 18 charts 1 FDA

MyeloidOther hematologic neoplasm

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04997902 2026-06-05

Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

Phase 1/2 Completed

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Recurrence

NCT05017012 2026-06-05

MK-3475A-C18

Phase 1 Completed

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT05050097 2026-06-05

MonumenTAL-2

Phase 1 Active not recruiting

Multiple Myeloma

NCT05160584 2026-06-05

MoMMent

Multiple Myeloma

NCT05201781 2026-06-05

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

Phase 4 Recruiting

Multiple Myeloma

NCT05316155 2026-06-05

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

Phase 1/2 Recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT05355701 2026-06-05

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

Phase 1 Recruiting

CNSDermatologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Glioma, Melanoma, Thyroid Neoplasms